title: Sequential emergence of ABL-kinase mutations with loss of unmutated BCR-ABL allele during targeted therapies of CML.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Sorel
authors.forename: Lydia
authors.initials: L
authors.lastname: Roy
authors.forename: Géraldine
authors.initials: G
authors.lastname: Martineau
authors.forename: François
authors.initials: F
authors.lastname: Guilhot
authors.forename: Ali G
authors.initials: AG
authors.lastname: Turhan
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Chomel
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides; D000069439:Dasatinib; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D016313:Genes, abl; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics*; D009154:Mutation; D010879:Piperazines / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage; D013844:Thiazoles / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; D000069439:Dasatinib